Literature DB >> 25939274

FTD and ALS--translating mouse studies into clinical trials.

Lars M Ittner1, Glenda M Halliday2, Jillian J Kril3, Jürgen Götz4, John R Hodges2, Matthew C Kiernan5.   

Abstract

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are related neurodegenerative disorders, which are characterized by a rapid decline in cognitive and motor functions, and short survival. Although the clinical and neuropathological characterization of these diseases has progressed--in part--through animal studies of pathogenetic mechanisms, the translation of findings from rodent models to clinical practice has generally not been successful. This article discusses the gap between preclinical animal studies in mice and clinical trials in patients with FTD or ALS. We outline how to better design preclinical studies, and present strategies to improve mouse models to overcome the translational shortfall. This new approach could help identify drugs that are more likely to achieve a therapeutic benefit for patients.

Entities:  

Mesh:

Year:  2015        PMID: 25939274     DOI: 10.1038/nrneurol.2015.65

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  121 in total

1.  Core features of frontotemporal dementia recapitulated in progranulin knockout mice.

Authors:  N Ghoshal; J T Dearborn; D F Wozniak; N J Cairns
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

2.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Authors:  Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

3.  The seeds of neurodegeneration: prion-like spreading in ALS.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

4.  Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone.

Authors:  Sara K Custer; Manuela Neumann; Hongbo Lu; Alexander C Wright; J Paul Taylor
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

5.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

6.  Design, power, and interpretation of studies in the standard murine model of ALS.

Authors:  Sean Scott; Janice E Kranz; Jeff Cole; John M Lincecum; Kenneth Thompson; Nancy Kelly; Alan Bostrom; Jill Theodoss; Bashar M Al-Nakhala; Fernando G Vieira; Jeyanthi Ramasubbu; James A Heywood
Journal:  Amyotroph Lateral Scler       Date:  2008

7.  Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Authors:  David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

8.  Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice.

Authors:  H Z Yin; A Nalbandian; C-I Hsu; S Li; K J Llewellyn; T Mozaffar; V E Kimonis; J H Weiss
Journal:  Cell Death Dis       Date:  2012-08-16       Impact factor: 8.469

9.  VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease.

Authors:  Mallikarjun Badadani; Angèle Nalbandian; Giles D Watts; Jouni Vesa; Masashi Kitazawa; Hailing Su; Jasmin Tanaja; Eric Dec; Douglas C Wallace; Jogeshwar Mukherjee; Vincent Caiozzo; Matthew Warman; Virginia E Kimonis
Journal:  PLoS One       Date:  2010-10-05       Impact factor: 3.240

10.  Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.

Authors:  Maria Armakola; Matthew J Higgins; Matthew D Figley; Sami J Barmada; Emily A Scarborough; Zamia Diaz; Xiaodong Fang; James Shorter; Nevan J Krogan; Steven Finkbeiner; Robert V Farese; Aaron D Gitler
Journal:  Nat Genet       Date:  2012-10-28       Impact factor: 38.330

View more
  23 in total

Review 1.  Toward precision medicine in amyotrophic lateral sclerosis.

Authors:  Zhang-Yu Zou; Chang-Yun Liu; Chun-Hui Che; Hua-Pin Huang
Journal:  Ann Transl Med       Date:  2016-01

2.  CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation.

Authors:  Yazi D Ke; Gabriella Chan; Kristie Stefanoska; Carol Au; Mian Bi; Julius Müller; Magdalena Przybyla; Astrid Feiten; Emmanuel Prikas; Glenda M Halliday; Olivier Piguet; Matthew C Kiernan; Michael Kassiou; John R Hodges; Clement T Loy; John S Mattick; Arne Ittner; Jillian J Kril; Greg T Sutherland; Lars M Ittner
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

3.  Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage.

Authors:  Sarah J Hill; Daniel A Mordes; Lisa A Cameron; Donna S Neuberg; Serena Landini; Kevin Eggan; David M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

Review 4.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

Review 5.  Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.

Authors:  Diane Moujalled; Anthony R White
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

6.  Power spectral analysis of hypoglossal nerve activity during intermittent hypoxia-induced long-term facilitation in mice.

Authors:  Mai K ElMallah; David A Stanley; Kun-Ze Lee; Sara M F Turner; Kristi A Streeter; David M Baekey; David D Fuller
Journal:  J Neurophysiol       Date:  2015-12-16       Impact factor: 2.714

Review 7.  ALS: Recent Developments from Genetics Studies.

Authors:  Martine Therrien; Patrick A Dion; Guy A Rouleau
Journal:  Curr Neurol Neurosci Rep       Date:  2016-06       Impact factor: 5.081

Review 8.  Frontotemporal Lobar Degeneration and MicroRNAs.

Authors:  Paola Piscopo; Diego Albani; Anna E Castellano; Gianluigi Forloni; Annamaria Confaloni
Journal:  Front Aging Neurosci       Date:  2016-02-09       Impact factor: 5.750

Review 9.  Tau physiology and pathomechanisms in frontotemporal lobar degeneration.

Authors:  Liviu-Gabriel Bodea; Anne Eckert; Lars Matthias Ittner; Olivier Piguet; Jürgen Götz
Journal:  J Neurochem       Date:  2016-06-15       Impact factor: 5.372

Review 10.  Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders.

Authors:  Stefano Puglisi-Allegra; Stefano Ruggieri; Francesco Fornai
Journal:  Transl Psychiatry       Date:  2021-07-05       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.